Confirm the Safety and Performance of Avance Solo NPWT System (ASOLO-SW)
A Prospective, Open, Non-comparative, Post-market Clinical Follow-up Investigation to Confirm Safety and Performance of Avance Solo NPWT System in Low to Moderate Exuding Acute (Traumatic Wounds and Flaps and Grafts), as Well as Subacute (e.g., Dehisced Wounds) Wounds
Sponsor: Molnlycke Health Care AB
Listed as NCT04754048, this NA trial focuses on Acute Wound and Dehiscence and remains completed. Sponsored by Molnlycke Health Care AB, it has been updated 6 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Mar 2023 — Jul 2024 [monthly]
Completed NA
Status: Recruiting → Completed
-
Sep 2021 — Mar 2023 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Mar 2021 — Sep 2021 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Molnlycke Health Care AB
- Syntactx
For direct contact, visit the study record on ClinicalTrials.gov .